DRIO
DarioHealth Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$4.49
−6.85%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.32
From 52W high−72.27%
Volume30891.00
Market cap$44.00M
P/E (TTM)6.5x
P/S (TTM)2.1x
Div yield—
Key dataOct 19, 2026
Open
$5.32
From 52W high
−72.27%
Volume
30891.00
Market cap
$44.00M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
6.5x
RSI (14)
29.7
MomentumView details →
1D Return
−6.85%
YTD Return
−58.26%
SummaryUpdated Jun 1, 2026
DarioHealth Corp. (NASDAQ:DRIO) is a digital therapeutics company that has undergone significant transformation since its founding. Originally incorporated in 2011 as LabStyle Innovations Corp., the company changed its name to DarioHealth Corp. in July 2016 and went public the same year. Based in New York, DarioHealth has evolved from a direct-to-consumer diabetes management company into a comprehensive digital health platform serving multiple chronic conditions through business-to-business partnerships with employers, health plans, and pharmaceutical companies across the United States, Canada, European Union, Australia, and New Zealand.
Similar companies
Latest newsMore news →
DarioHealth Corp. announced the results of an independent Aon review supporting the clinical and cost-savings impact of its multi-condition digital health platform.13d agoDarioHealth Corp. announced a new contract with a leading New Jersey health plan covering approximately 1.5 million lives, secured through channel partner Amwell, with its cardiometabolic suite and provider-backed care expected to launch and begin generating revenue in the first quarter of 2027.32d ago